• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Can Pain Following Gyn Oncology Surgery Be Managed with a Very Restrictive Opioid Protocol?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Mark et al. (JAMA Open, 2018) assessed whether postsurgical acute pain can be managed post-discharge with a very restrictive opioid policy in place

METHODS:

  • Prospective Case | Retrospective control cohort study
    • Controls: Prior to 2017, Gyn Onc prescribed opioids “liberally”
    • Cases: From June 26, 2017, through June 30, 2018, an ultrarestrictive opioid prescription protocol (UROPP) was implemented
  • UROPP protocol
    • Ambulatory or minimally invasive surgery (laparoscopic or robotic approach): Not routinely prescribed opioids at discharge
      • Opioids were prescribed if more than 5 doses of oral or intravenous opioids were required while in the hospital
    • Laparotomy: Provided a 3-day opioid pain medication supply at discharge
  • Total number of opioid pain medications prescribed in the 60-day perioperative period, requests for opioid prescription refills, and postoperative pain scores and complications were evaluated
  • Primary Outcomes
    • Mean postoperative pain score 2 weeks after surgery
    • New requests for opioid refills within 30 days after surgery
  • Secondary Outcomes
    • Complications within 30 days after the procedure, based upon the American College of Surgeons National Surgical Quality Improvement Program

RESULTS:

  • Patient demographics and procedure characteristics were not statistically different between the 2 cohorts of women
    • 605 cases | 626 controls
  • Mean (SD) number of opioid tablets given at discharge after laparotomy (P < .001)
    • Controls: 43.6 (17.0)
    • Cases: 12.1 (8.9)
  • Mean (SD) number of opioid tablets given at discharge after laparoscopic or robotic surgery (P < .001)
    • Controls: 38.4 (17.4)
    • Cases: 1.3 (3.7)
  • Mean (SD) number of opioid tablets given at discharge after ambulatory surgery (P < .001)
    • Controls: 13.9 (16.6)
    • Cases: 0.2 (2.1)
  • There was no significant increase in
    • Number of refill requests: 16.6% in controls vs 16.5% in cases (P=.99)
    • The mean postoperative visit pain scores: 1.4 in controls vs 1.1 in cases (P = .06)
    • Number of complications: 6.7% in controls vs 4.8% in cases (P = .15)

CONCLUSION:

  • An ultrarestrictive opioid policy used by a gyn oncology service was not associated with increased refills, postoperative pain or complications
  • The authors note that the protocol is sustainable and 98% of the health care professionals are in compliance

Learn More – Primary Sources:

Ultrarestrictive Opioid Prescription Protocol for Pain Management After Gynecologic and Abdominal Surgery

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Are the Number of Opioid Pills Prescribed Related to Consumption in Post-Op Patients?
Do Non-Opioids Work as Well as Opioids for Acute Extremity Pain? 
Should Opioid Medications Be Left Out of the Treatment Plan?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site